Cumberland Pharmaceuticals Inc.
CPIX
$2.28
$0.125.56%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -8.73% | 10.04% | 37.84% | 24.49% | -9.92% |
| Total Other Revenue | -- | -- | -- | -34.76% | -- |
| Total Revenue | -8.73% | 10.04% | 37.84% | 11.57% | -9.92% |
| Cost of Revenue | -25.26% | 17.56% | -9.51% | 29.18% | -25.07% |
| Gross Profit | -5.92% | 8.46% | 48.61% | 8.13% | -6.70% |
| SG&A Expenses | -0.95% | 1.33% | 2.64% | -7.92% | -0.20% |
| Depreciation & Amortization | -6.37% | -8.49% | -9.49% | 22.09% | -8.25% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.85% | 6.52% | 0.52% | 0.73% | -9.81% |
| Operating Income | -15.99% | 27.19% | 169.11% | 35.04% | 9.23% |
| Income Before Tax | -27.39% | 33.15% | 166.31% | 68.80% | -44.42% |
| Income Tax Expenses | -50.00% | -50.00% | -50.00% | -328.00% | 65.22% |
| Earnings from Continuing Operations | -26.81% | 33.32% | 165.61% | 69.83% | -44.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 216.90% | -132.35% | 120.32% | -128.95% | -151.08% |
| Net Income | -25.69% | 31.77% | 164.59% | 69.75% | -47.16% |
| EBIT | -15.99% | 27.19% | 169.11% | 35.04% | 9.23% |
| EBITDA | -60.36% | 153.90% | 423.34% | 78.43% | 6.78% |
| EPS Basic | -18.02% | 35.63% | 160.90% | 69.33% | -49.52% |
| Normalized Basic EPS | -2.15% | 34.61% | 160.99% | 31.89% | -30.63% |
| EPS Diluted | -18.18% | 37.50% | 157.14% | 68.51% | -49.66% |
| Normalized Diluted EPS | -2.15% | 34.61% | 159.72% | 31.89% | -30.63% |
| Average Basic Shares Outstanding | 6.44% | 5.97% | 5.99% | -1.36% | -1.57% |
| Average Diluted Shares Outstanding | 6.44% | 5.97% | 8.24% | -1.36% | -1.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |